NASDAQ:BBH

VanEck Vectors Biotech ETF Competitors

$180.28
+1.58 (+0.88 %)
(As of 04/14/2021 04:00 PM ET)
Add
Compare
Today's Range
$179.80
Now: $180.28
$182.09
50-Day Range
$167.43
MA: $175.91
$184.77
52-Week Range
$136.96
Now: $180.28
$197.28
Volume12,997 shs
Average Volume12,942 shs
Market Capitalization$508.75 million
P/E RatioN/A
Dividend Yield0.35%
Beta1.01

Competitors

VanEck Vectors Biotech ETF (NASDAQ:BBH) Vs. PTY, GSBD, HTGC, RVT, GAB, and TY

Should you be buying BBH stock or one of its competitors? Companies in the industry of "investment offices, not elsewhere classified" are considered alternatives and competitors to VanEck Vectors Biotech ETF, including PIMCO Corporate & Income Opportunity Fund (PTY), Goldman Sachs BDC (GSBD), Hercules Capital (HTGC), Royce Value Trust (RVT), The Gabelli Equity Trust (GAB), and Tri-Continental (TY).

PIMCO Corporate & Income Opportunity Fund (NYSE:PTY) and VanEck Vectors Biotech ETF (NASDAQ:BBH) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Institutional and Insider Ownership

6.9% of PIMCO Corporate & Income Opportunity Fund shares are held by institutional investors. Comparatively, 28.1% of VanEck Vectors Biotech ETF shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dividends

PIMCO Corporate & Income Opportunity Fund pays an annual dividend of $1.56 per share and has a dividend yield of 8.3%. VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. PIMCO Corporate & Income Opportunity Fund has increased its dividend for 1 consecutive years. PIMCO Corporate & Income Opportunity Fund is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current ratings for PIMCO Corporate & Income Opportunity Fund and VanEck Vectors Biotech ETF, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PIMCO Corporate & Income Opportunity Fund0000N/A
VanEck Vectors Biotech ETF0000N/A

Earnings and Valuation

This table compares PIMCO Corporate & Income Opportunity Fund and VanEck Vectors Biotech ETF's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PIMCO Corporate & Income Opportunity FundN/AN/AN/AN/AN/A
VanEck Vectors Biotech ETFN/AN/AN/AN/AN/A

Profitability

This table compares PIMCO Corporate & Income Opportunity Fund and VanEck Vectors Biotech ETF's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PIMCO Corporate & Income Opportunity FundN/AN/AN/A
VanEck Vectors Biotech ETFN/AN/AN/A

Volatility and Risk

PIMCO Corporate & Income Opportunity Fund has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, VanEck Vectors Biotech ETF has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Goldman Sachs BDC (NYSE:GSBD) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 13.8% of Goldman Sachs BDC shares are owned by institutional investors. 0.3% of Goldman Sachs BDC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Goldman Sachs BDC pays an annual dividend of $1.80 per share and has a dividend yield of 9.3%. Goldman Sachs BDC pays out 90.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Goldman Sachs BDC has raised its dividend for 1 consecutive years. Goldman Sachs BDC is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and Goldman Sachs BDC, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VanEck Vectors Biotech ETF0000N/A
Goldman Sachs BDC02102.33

Goldman Sachs BDC has a consensus target price of $15.9167, indicating a potential downside of 17.91%. Given Goldman Sachs BDC's higher possible upside, analysts plainly believe Goldman Sachs BDC is more favorable than VanEck Vectors Biotech ETF.

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and Goldman Sachs BDC's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VanEck Vectors Biotech ETFN/AN/AN/AN/AN/A
Goldman Sachs BDC$147.26 million13.38$36.15 million$1.989.79

Goldman Sachs BDC has higher revenue and earnings than VanEck Vectors Biotech ETF.

Profitability

This table compares VanEck Vectors Biotech ETF and Goldman Sachs BDC's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VanEck Vectors Biotech ETFN/AN/AN/A
Goldman Sachs BDC9.56%11.79%4.83%

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Goldman Sachs BDC has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Summary

Goldman Sachs BDC beats VanEck Vectors Biotech ETF on 10 of the 12 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Hercules Capital (NYSE:HTGC) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 28.9% of Hercules Capital shares are owned by institutional investors. 3.3% of Hercules Capital shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Hercules Capital pays an annual dividend of $1.28 per share and has a dividend yield of 7.6%. Hercules Capital pays out 90.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hercules Capital has raised its dividend for 1 consecutive years. Hercules Capital is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and Hercules Capital, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VanEck Vectors Biotech ETF0000N/A
Hercules Capital00803.00

Hercules Capital has a consensus target price of $13.8438, indicating a potential downside of 18.08%. Given Hercules Capital's higher possible upside, analysts plainly believe Hercules Capital is more favorable than VanEck Vectors Biotech ETF.

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and Hercules Capital's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VanEck Vectors Biotech ETFN/AN/AN/AN/AN/A
Hercules Capital$267.87 million7.29$173.60 million$1.4111.99

Hercules Capital has higher revenue and earnings than VanEck Vectors Biotech ETF.

Profitability

This table compares VanEck Vectors Biotech ETF and Hercules Capital's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VanEck Vectors Biotech ETFN/AN/AN/A
Hercules Capital42.72%13.58%6.31%

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Hercules Capital has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Summary

Hercules Capital beats VanEck Vectors Biotech ETF on 11 of the 12 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Royce Value Trust (NYSE:RVT) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 24.6% of Royce Value Trust shares are owned by institutional investors. 0.5% of Royce Value Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Royce Value Trust pays an annual dividend of $1.02 per share and has a dividend yield of 5.5%.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and Royce Value Trust, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VanEck Vectors Biotech ETF0000N/A
Royce Value Trust0000N/A

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and Royce Value Trust's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VanEck Vectors Biotech ETFN/AN/AN/AN/AN/A
Royce Value TrustN/AN/AN/AN/AN/A

Profitability

This table compares VanEck Vectors Biotech ETF and Royce Value Trust's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VanEck Vectors Biotech ETFN/AN/AN/A
Royce Value TrustN/AN/AN/A

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Royce Value Trust has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500.

Summary

Royce Value Trust beats VanEck Vectors Biotech ETF on 3 of the 4 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and The Gabelli Equity Trust (NYSE:GAB) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are owned by institutional investors. Comparatively, 5.6% of The Gabelli Equity Trust shares are owned by institutional investors. 1.0% of The Gabelli Equity Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. The Gabelli Equity Trust pays an annual dividend of $0.60 per share and has a dividend yield of 8.6%. The Gabelli Equity Trust has raised its dividend for 1 consecutive years. The Gabelli Equity Trust is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for VanEck Vectors Biotech ETF and The Gabelli Equity Trust, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VanEck Vectors Biotech ETF0000N/A
The Gabelli Equity Trust0000N/A

Valuation and Earnings

This table compares VanEck Vectors Biotech ETF and The Gabelli Equity Trust's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VanEck Vectors Biotech ETFN/AN/AN/AN/AN/A
The Gabelli Equity TrustN/AN/AN/AN/AN/A

Profitability

This table compares VanEck Vectors Biotech ETF and The Gabelli Equity Trust's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VanEck Vectors Biotech ETFN/AN/AN/A
The Gabelli Equity TrustN/AN/AN/A

Volatility and Risk

VanEck Vectors Biotech ETF has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, The Gabelli Equity Trust has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Summary

The Gabelli Equity Trust beats VanEck Vectors Biotech ETF on 4 of the 5 factors compared between the two stocks.

VanEck Vectors Biotech ETF (NASDAQ:BBH) and Tri-Continental (NYSE:TY) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Risk & Volatility

VanEck Vectors Biotech ETF has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Tri-Continental has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for VanEck Vectors Biotech ETF and Tri-Continental, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VanEck Vectors Biotech ETF0000N/A
Tri-Continental0000N/A

Profitability

This table compares VanEck Vectors Biotech ETF and Tri-Continental's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VanEck Vectors Biotech ETFN/AN/AN/A
Tri-ContinentalN/AN/AN/A

Dividends

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and has a dividend yield of 0.3%. Tri-Continental pays an annual dividend of $1.62 per share and has a dividend yield of 4.8%.

Institutional and Insider Ownership

28.1% of VanEck Vectors Biotech ETF shares are held by institutional investors. Comparatively, 8.8% of Tri-Continental shares are held by institutional investors. 8.7% of Tri-Continental shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares VanEck Vectors Biotech ETF and Tri-Continental's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VanEck Vectors Biotech ETFN/AN/AN/AN/AN/A
Tri-ContinentalN/AN/AN/AN/AN/A

Summary

Tri-Continental beats VanEck Vectors Biotech ETF on 3 of the 4 factors compared between the two stocks.


VanEck Vectors Biotech ETF Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PTY
PIMCO Corporate & Income Opportunity Fund
0.8$18.69+0.3%$1.98 billionN/A0.00
Goldman Sachs BDC logo
GSBD
Goldman Sachs BDC
1.4$19.39+0.0%$1.97 billion$147.26 million64.63
Hercules Capital logo
HTGC
Hercules Capital
1.5$16.91+0.1%$1.95 billion$267.87 million15.66
RVT
Royce Value Trust
1.0$18.67+0.5%$1.87 billionN/A0.00Increase in Short Interest
News Coverage
The Gabelli Equity Trust logo
GAB
The Gabelli Equity Trust
0.8$6.97+0.4%$1.83 billionN/A0.00
Tri-Continental logo
TY
Tri-Continental
0.9$33.45+0.3%$1.80 billionN/A0.00
Liberty All-Star Equity Fund logo
USA
Liberty All-Star Equity Fund
1.2$8.24+0.2%$1.75 billionN/A0.00Dividend Increase
Decrease in Short Interest
News Coverage
Liberty All-Star Equity Fund logo
USA
Liberty All-Star Equity Fund
0.9$8.24+0.2%$1.75 billionN/A0.00Dividend Increase
Decrease in Short Interest
News Coverage
Tortoise Energy Infrastructure logo
TYG
Tortoise Energy Infrastructure
0.7$25.59+2.4%$1.34 billionN/A0.00Increase in Short Interest
News Coverage
BIF
Boulder Growth & Income Fund
0.8$13.15+0.1%$1.29 billionN/A0.00
QQQX
Nuveen Nasdaq 100 Dynamic Overwrite Fund
0.3$28.24+0.6%$1.18 billionN/A0.00Decrease in Short Interest
News Coverage
AWF
AllianceBernstein Global High Income Fund
0.8$11.96+0.0%$1.03 billionN/A0.00Decrease in Short Interest
HQH
Tekla Healthcare Investors
0.8$24.34+0.7%$1.02 billionN/A0.00Increase in Short Interest
News Coverage
GAM
General American Investors
0.8$41.56+0.0%$1.02 billionN/A0.00Decrease in Short Interest
News Coverage
MYI
BlackRock MuniYield Quality Fund III
0.8$14.34+0.2%$979.32 millionN/A0.00Increase in Short Interest
Apollo Investment logo
AINV
Apollo Investment
1.2$14.16+0.1%$925.37 million$276.92 million-8.53Decrease in Short Interest
VMO
Invesco Municipal Opportunity Trust
0.9$13.43+0.7%$899.25 millionN/A0.00Decrease in Short Interest
PHK
PIMCO High Income Fund
0.9$6.81+0.6%$894.41 millionN/A0.00
SLR Investment logo
SLRC
SLR Investment
1.9$18.81+1.3%$805.48 million$154.71 million-156.75
TDF
Templeton Dragon Fund
1.0$22.45+0.1%$757.89 millionN/A0.00Increase in Short Interest
News Coverage
VGM
Invesco Trust for Investment Grade Municipals
1.0$13.73+0.1%$745.59 millionN/A0.00Decrease in Short Interest
BTO
John Hancock Financial Opportunities Fund
1.2$39.47+0.8%$734.10 millionN/A0.00Increase in Short Interest
VKQ
Invesco Municipal Trust
0.8$13.30+0.5%$732.44 millionN/A0.00Increase in Short Interest
GIM
Templeton Global Income Fund
1.1$5.39+0.7%$728.40 millionN/A0.00News Coverage
MYD
BlackRock MuniYield Fund
0.9$14.73+0.1%$690.66 millionN/A0.00Decrease in Short Interest
Invesco California Value Municipal Income Trust logo
VCV
Invesco California Value Municipal Income Trust
0.8$13.14+0.7%$624.70 millionN/A0.00Decrease in Short Interest
News Coverage
MUC
BlackRock MuniHoldings California Quality Fund
0.3$15.08+0.1%$617.90 millionN/A0.00
MVF
BlackRock MuniVest Fund
0.3$9.41+0.4%$612.74 millionN/A0.00Decrease in Short Interest
News Coverage
MMU
Western Asset Managed Municipals Fund
0.9$13.20+0.2%$572.46 millionN/A0.00Decrease in Short Interest
IFN
The India Fund
0.8$20.96+0.2%$565.11 millionN/A0.00Decrease in Short Interest
MFL
BlackRock MuniHoldings Investment Quality Fund
0.7$14.68+0.9%$551.39 millionN/A0.00Decrease in Short Interest
MUA
BlackRock MuniAssets Fund
0.9$15.19+0.7%$547.48 millionN/A0.00Increase in Short Interest
EVN
Eaton Vance Municipal Income Trust
0.8$13.77+0.1%$545.42 millionN/A0.00Increase in Short Interest
News Coverage
LEO
BNY Mellon Strategic Municipals
0.7$8.65+1.2%$544.25 millionN/A0.00Increase in Short Interest
NQP
Nuveen Pennsylvania Quality Municipal Income Fund
0.8$14.41+0.4%$540.93 millionN/A0.00Decrease in Short Interest
BlackRock MuniYield New York Quality Fund logo
MYN
BlackRock MuniYield New York Quality Fund
0.9$13.68+0.5%$538.78 millionN/A0.00Decrease in Short Interest
DSU
BlackRock Debt Strategies Fund
0.8$11.11+0.1%$519.68 millionN/A0.00Increase in Short Interest
News Coverage
MCA
BlackRock MuniYield California Quality Fund
0.8$14.96+0.2%$515.75 millionN/A0.00Decrease in Short Interest
News Coverage
RMT
Royce Micro-Cap Trust
1.2$11.77+0.4%$509.43 millionN/A0.00Increase in Short Interest
News Coverage
DSM
BNY Mellon Strategic Municipal Bond Fund
0.9$8.04+0.7%$503.90 millionN/A0.00Increase in Short Interest
MQY
BlackRock MuniYield Quality Fund
0.8$16.11+0.3%$493.28 millionN/A0.00
PPT
Putnam Premier Income Trust
0.8$4.74+0.2%$490.30 millionN/A0.00
KTF
DWS Municipal Income Trust
0.8$11.87+0.0%$468.88 millionN/A0.00Dividend Announcement
Decrease in Short Interest
PMO
Putnam Municipal Opportunities Trust
0.8$13.88+1.1%$468.33 millionN/A0.00
MUJ
BlackRock MuniHoldings New Jersey Quality Fund
0.8$15.12+0.1%$455.52 millionN/A0.00
MIY
BlackRock MuniYield Michigan Quality Fund
0.9$15.21+0.1%$448.85 millionN/A0.00
HQL
Tekla Life Sciences Investors
0.9$19.71+0.9%$444.73 millionN/A0.00Increase in Short Interest
MHN
BlackRock MuniHoldings New York Quality Fund
0.8$14.32+0.3%$444.57 millionN/A0.00Decrease in Short Interest
News Coverage
ZTR
Virtus Total Return Fund
0.8$9.35+0.1%$442.49 millionN/A0.00
MIN
MFS Intermediate Income Trust
1.0$3.66+0.3%$425.47 millionN/A0.00Decrease in Short Interest
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.